Shionogi

FDA clears Dova drug for liver-related low blood platelets

Dova may not have too long before it faces direct competition in its first indication, however, as Japanese drugmaker Shionogi filed for approval of its lusutrombopag (S-888711) candidate in ... Shionogi has a priority review for its marketing

Shionogi aims for digital transformation

To ensure sustainable growth and enhance our specialised business operations, we established six subsidiaries, including Shionogi Digital Science in April 2017. ... The consultants will also help Shionogi enhance its IT division’s digital talent and

ViiV starts trial of HIV-preventing injections for women

ViiV - majority owned by GlaxoSmithKline, with Pfizer and Shionogi as shareholders - is planning to enrol 3, 200 women aged between 18 and 45 into the study, which will be carried out

Japanese pharma pulls no punches with post-Brexit UK

The level of investment on the pharmaceutical side is considerable. The Japanese Pharmaceutical Group (JPG), an association of nine drugmakers - Astellas, Chugai, Daiichi-Sankyo, Eisai, Kowa, Mitsubishi Tanabe, Otsuka, Shionogi and

Deal Watch March 2017

Duchesnay, the Canadian women’s health company, has acquired from Shionogi the rights to market Osphena, another oral treatment for dyspareunia, in North America.

[ Previous 5 results ] 3 4 5 6 7 8 9 10 11 12 [ Next 5 results ]